Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Study of General Foetal Movements Using Ultrasound

NCT07868185 · tracked via the Priya Life Science France tracker
Sponsor
François FARGES
Phase
Not applicable
Started
2023-02-14
Last updated
2026-10-09

Condition(s) studied

Pregnant WomanFoetus Abnormal General Movements

Investigational drug(s) / intervention(s)

External or endovaginal ultrasound

External or endovaginal ultrasound: Endovaginal or external ultrasound specifically for research at 13, 17 (if amniocentesis), 23 and 33 weeks of amenorrhoea (+/- 10 days) (on average 10% endovaginal / 90% external ultrasound). Each patient will undergo one to four additional ultrasound scans.

Study summary

This research explores General Movements (GMs) in a reference population. Abnormal general movements in babies are predictive of autism spectrum disorders or neurodevelopmental deficits.

General movements have received little attention in the context of foetuses, which is why developing a reading grid to analyse general movements in foetuses could be a valuable tool for facilitating early diagnosis and prompt treatment of at-risk babies.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Patient aged over 18 * Pregnant from 13 weeks of amenorrhoea * Indication for an ultrasound scan as part of the usual monitoring of her pregnancy * With no particular history or who has had a child with autism spectrum disorders or neurodevelopmental disorders * Able to understand the benefits and constraints of the research * Having given signed consent to participate, as well as that of his/her spouse. * Beneficiary of a social security scheme or entitled person (excluding AME). Exclusion Criteria: * Pathological pregnancy * Under guardianship, curatorship or legal protection.

Primary outcome measure(s)

  • Quantitative and Qualitative Parameters of General Fetal Movements Assessed by Ultrasound Recordings Across Gestation — 9 months
    Presence, frequency, and characteristics of abnormal fetal movement patterns identified on ultrasound recordings obtained at 13, 17, 23, and 33 weeks of amenorrhea (±10 days). Recordings will be independently assessed by experts in fetal ultrasonography and General Movements Assessment using the General Movements Assessment grid adapted for preterm infants. Reported outcomes will include the occurrence and type of abnormal movement patterns at each assessment time point.

Trial sites (1)

FacilityCityRegionStatus
Groupe Hospitalier Diaconesses Croix Saint-Simon Paris Paris Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07868185 on ClinicalTrials.gov ↗ ← All trials in France